|1.||Castaño, Justo P: 2 articles (10/2015 - 05/2010)|
|2.||Gingras, Marie-Claude: 2 articles (12/2011 - 07/2011)|
|3.||Gunz, G: 2 articles (07/2001 - 01/2001)|
|4.||Jaquet, P: 2 articles (07/2001 - 01/2001)|
|5.||Saveanu, A: 2 articles (07/2001 - 01/2001)|
|6.||Enjalbert, A: 2 articles (07/2001 - 01/2001)|
|7.||Dufour, H: 2 articles (07/2001 - 01/2001)|
|8.||Marina, Djordje: 1 article (10/2015)|
|9.||Casar-Borota, Olivera: 1 article (10/2015)|
|10.||Feldt-Rasmussen, Ulla: 1 article (10/2015)|
10/01/2011 - "The aim of this study was to characterize the genetic variance of somatostatin receptor 5 (SSTR5) and investigate the possible correlation of such variants with acromegaly risk and different disease characteristics. "
10/01/2011 - "Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly."
10/01/2015 - "Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache."
12/01/2011 - "Somatostatin receptor type 5 (SSTR5) P335L is a hypofunctional, single nucleotide polymorphism of SSTR5 with implications in the diagnostics and therapy of pancreatic neuroendocrine neoplasms. "
01/01/2001 - "These data indicate that due to heterogeneous expression of SSTR2 and SSTR5 receptor subtypes, in GH-secreting tumors, a bispecific analog, such as BIM-23244, that can activate both receptors could achieve better control of GH hypersecretion in a larger number of acromegalic patients."
01/01/2007 - "We performed immunohistochemistry for Somatostatin receptor 2A (SSTR2A) and Somatostatin receptor 5 (SSTR5) on the surgical specimens from all patients, which we scored according to the number of tumor cells staining positive at the surface membrane (3+: >50%, 2+: 25-50%, 1+: <25%). "
07/01/2000 - "We have previously shown that pharmacological doses of thyroid hormone (levothyroxine [LT4]) inhibit growth of murine TtT-97 thyrotropic tumors in association with upregulation of somatostatin receptor type 5 (sst5) mRNA and somatostatin receptor binding. "
08/01/1995 - "The effects of octreotide, a long-acting somatostatin agonist selective of the sstr2/sstr3/sstr5 receptor subtypes, on ectopic GH secretion and tumor growth were investigated in Wistar-Furth female rats implanted with GH secreting (GC) cells which express mostly somatostatin receptors of the sstr1 and sstr2 subtypes. "
|4.||ACTH-Secreting Pituitary Adenoma
04/01/2012 - "Two molecules potentially act directly to suppress the ACTH secretion by the corticotroph adenoma: agonists of the D2 Dopamine receptor and of the somatostatin receptor type 5. Their efficacy remains modest (20 to 30% of the patients actually normalize urinary cortisol). "
04/01/2005 - "The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5."
|5.||Mood Disorders (Mood Disorder)
|1.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|2.||Somatostatin Receptors (Somatostatin Receptor)
|3.||Adrenocorticotropic Hormone (ACTH)
|4.||somatostatin receptor type 1
|5.||somatostatin receptor 5
|6.||Dopamine D2 Receptors (Dopamine D2 Receptor)
|9.||Messenger RNA (mRNA)
|10.||Dopamine Receptors (Dopamine Receptor)